vs
Side-by-side financial comparison of CytoMed Therapeutics Ltd (GDTC) and HWH International Inc. (HWH). Click either name above to swap in a different company.
HWH International Inc. is the larger business by last-quarter revenue ($206.8K vs $115.4K, roughly 1.8× CytoMed Therapeutics Ltd). HWH International Inc. produced more free cash flow last quarter ($-217.9K vs $-855.4K).
CytoMed Therapeutics Ltd is a clinical-stage biopharmaceutical company focused on developing innovative allogeneic chimeric antigen receptor (CAR-T) cell therapies for treating hematological malignancies and solid tumors. It primarily serves global oncology patient populations and advances candidates targeting unmet medical needs in the immuno-oncology segment.
HWH International Inc operates in the global luxury hospitality and lifestyle services industry, providing premium travel membership programs, curated high-end travel experiences, and exclusive access to luxury resorts, fine dining venues, and premium leisure facilities. Its key markets include North America, Asia Pacific, and Europe, serving high-net-worth individuals and corporate clients.
GDTC vs HWH — Head-to-Head
Income Statement — Q2 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $115.4K | $206.8K |
| Net Profit | — | $-291.0K |
| Gross Margin | — | 59.8% |
| Operating Margin | — | -142.7% |
| Net Margin | — | -140.7% |
| Revenue YoY | — | -40.2% |
| Net Profit YoY | — | 46.9% |
| EPS (diluted) | — | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | — | $206.8K | ||
| Q2 25 | $115.4K | $310.4K | ||
| Q4 24 | — | $287.1K | ||
| Q3 24 | — | $345.5K | ||
| Q2 24 | — | $334.9K | ||
| Q1 24 | — | $286.1K |
| Q3 25 | — | $-291.0K | ||
| Q2 25 | — | $83.4K | ||
| Q4 24 | — | $-476.7K | ||
| Q3 24 | — | $-548.5K | ||
| Q2 24 | — | $-387.9K | ||
| Q1 24 | — | $-1.3M |
| Q3 25 | — | 59.8% | ||
| Q2 25 | — | 48.0% | ||
| Q4 24 | — | 39.6% | ||
| Q3 24 | — | 46.3% | ||
| Q2 24 | — | 49.2% | ||
| Q1 24 | — | 57.1% |
| Q3 25 | — | -142.7% | ||
| Q2 25 | — | 24.5% | ||
| Q4 24 | — | -170.2% | ||
| Q3 24 | — | -155.5% | ||
| Q2 24 | — | -120.5% | ||
| Q1 24 | — | -467.1% |
| Q3 25 | — | -140.7% | ||
| Q2 25 | — | 26.9% | ||
| Q4 24 | — | -166.1% | ||
| Q3 24 | — | -158.7% | ||
| Q2 24 | — | -115.8% | ||
| Q1 24 | — | -467.2% |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $2.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | — | $2.8M |
| Total Assets | — | $5.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $2.9M | ||
| Q2 25 | — | $3.7M | ||
| Q4 24 | — | $4.4M | ||
| Q3 24 | — | $836.3K | ||
| Q2 24 | — | $958.9K | ||
| Q1 24 | — | $1.1M |
| Q3 25 | — | $2.8M | ||
| Q2 25 | — | $3.2M | ||
| Q4 24 | — | $2.8M | ||
| Q3 24 | — | $-374.9K | ||
| Q2 24 | — | $-3.6M | ||
| Q1 24 | — | $-3.1M |
| Q3 25 | — | $5.2M | ||
| Q2 25 | — | $10.6M | ||
| Q4 24 | — | $6.4M | ||
| Q3 24 | — | $2.9M | ||
| Q2 24 | — | $3.1M | ||
| Q1 24 | — | $2.6M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-855.3K | $-199.9K |
| Free Cash FlowOCF − Capex | $-855.4K | $-217.9K |
| FCF MarginFCF / Revenue | -741.5% | -105.4% |
| Capex IntensityCapex / Revenue | 0.0% | 8.7% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $-199.9K | ||
| Q2 25 | $-855.3K | $26.9K | ||
| Q4 24 | — | $-415.2K | ||
| Q3 24 | — | $-275.0K | ||
| Q2 24 | — | $-490.8K | ||
| Q1 24 | — | $-638.2K |
| Q3 25 | — | $-217.9K | ||
| Q2 25 | $-855.4K | — | ||
| Q4 24 | — | $-415.5K | ||
| Q3 24 | — | $-277.1K | ||
| Q2 24 | — | $-516.8K | ||
| Q1 24 | — | $-640.3K |
| Q3 25 | — | -105.4% | ||
| Q2 25 | -741.5% | — | ||
| Q4 24 | — | -144.7% | ||
| Q3 24 | — | -80.2% | ||
| Q2 24 | — | -154.3% | ||
| Q1 24 | — | -223.8% |
| Q3 25 | — | 8.7% | ||
| Q2 25 | 0.0% | — | ||
| Q4 24 | — | 0.1% | ||
| Q3 24 | — | 0.6% | ||
| Q2 24 | — | 7.7% | ||
| Q1 24 | — | 0.7% |
| Q3 25 | — | — | ||
| Q2 25 | — | 0.32× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
